Gilteritinib for the Treatment of ALK NSCLC
Gilteritinib for the Treatment of ALK NSCLC
Recruiting · NCT06225427 · Registry updated 2026-06-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gilteritinib for the Treatment of ALK NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-06-26 | NCT06225427 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Michigan Rogel Cancer Center | 63 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | United States | 392 |
| Georgetown University | Washington D.C. | United States | 38 |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | United States | 88 |